Merck price target raised to $134 from $132 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Merck to $134 from $132 and keeps an Equal Weight rating on the shares. In the first quarter of the Winrevair/Sotatercept PAH launch, the firm’s analysis suggests an initial bolus in Q2 will help build confidence that the drug can beat consensus for the year, the analyst tells investors in an earnings preview note for the Biopharma group.